ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Molecular insight into the therapeutic potential of miR-34a in retinoblastoma.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoblastoma (RB) is the predominant type of eye cancer in children, particularly affecting those under three. Early diagnosis is crucial as RB can be fatal if left untreated. MicroRNAs (miRNAs), non-coding RNAs, have emerged as significant regulators of various cellular processes and are increasingly recognized for their influence on RB development and treatment resistance. Dysregulation of miR-34a expression has been implicated in various aspects of tumorigenesis, including processes critical for cancer progression: epithelial-mesenchymal transition (EMT) within the tumor, invasive growth, and metastasis. Furthermore, a deeper understanding of the molecular mechanisms underlying miR-34a function in RB is crucial for the development of effective diagnostic tools and therapeutic strategies. The abundance of miR-34a is further fine-tuned through context-dependent feedback loops. This review comprehensively examines the current understanding of miR-34a's functions in various human diseases. We focus on how miR-34a expression is regulated and disrupted, its involvement in human cancers specifically RB, and its potential as a biomarker for disease diagnosis and prognosis. Additionally, we explore the potential of miR-34a as a novel therapeutic target in RB.
Indexed as
Identifiers
40694092What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.